 |
 |
|
|
|
| Octreotide Acetate |
 |
| C49H66N10O10S2 |
 |
| 83150-76-9 |
 |
| It is clinically mainly used to treat the following acromegalics, the gastroenteropancreatic endocrine tumors, the carcinoid accompanied with the features of carcinoid syndrome, the vasoactive intestinal peptide tumor, glucagonoma, gastrinoma/ Zollinger-Ellison Syndrome, insulinoma (be used for the prevention and maintenance of preoperation hypoglycemia) and growth hormone release factor adenoma. |
 |
Parameters of Product:
1 .Appearance :White powder
2 .Specific Optical Rotation (c=0.5,95%HAc) :-45.0~-55.0°
3 .Water Content(Karl Fischer) :≤6.0%
4 .Acetate Content(by HPLC) :≤15.0%
5 .Amino Acid Composition :±10% of theoretical
6 .Purity (by HPLC) :≥98.0%
7 .Single Impurity(by HPLC) :≤1.0%
8 .Peptide Content(by N%) :≥80%
9 .Assay(By Anhydrous, Acetic Acid-free ) :95.0~105.0%
10 .Bacterial Endotoxins :≤5EU/mg
|
|
|
|
|
|
